Embrace Prevention Care & NF2 Therapeutics

At its meeting on the morning of Tuesday, October 12, 2021, Beacon Angels members entertained new company funding proposals as follows:

  • Embrace Prevention Care (speaking in person, David Dlesk, CEO), which provides Personal Prevention Care, an integrated suite of geriatric telehealth and pharmacy services designed to prevent hospitalizations and lower costs of care for older adults with heart failure and other chronic conditions; and
  • NF2 Therapeutics (from en route to Montreal,  Michael Wootton, CEO), a biotechnology company developing gene replacement therapy to prevent deafness, loss of mobility and devastating brain tumors from NF2, and a targeted antibody-drug conjugate to treat meningiomas from NF2 and sporadic meningiomas. Both therapies are eligible for the FDA’s Orphan Drug Designation.

Members presented their due diligence report on Intraday, developing AI tools in the financial technology field to enable companies to forecast and deploy cash efficiently and more productive.

CEO Ron Murphy presented in person on the extension of Theromics’ fundraising round.

We heard updates on Beacon’s new portfolio companies:

  • AmplifiDx, offering a Molecular Point-of-Care biotechnology platform via the DX 1000 System for accurate, convenient, and affordable infectious disease testing; and
  • Hilltop BioSciences, a veterinary biotech company offering novel therapies for inflammatory diseases such as equine asthma and canine osteoarthritis.

About Angel Treaty

Dedicated to fostering due diligence sharing between angel groups.
This entry was posted in Beacon Angels Events, Boston angel investing, Boston Startups, Funding Presentations. Bookmark the permalink.